Erratum to Partial dysfunction of Treg activation in sickle cell disease [Am. J. Hematol, 89, (2014), 261-266], 10.1002/ajh.23629;Partial dysfunction of Treg activation in sickle cell disease

American Journal of Hematology

Volumn 89, Issue 3, 2014, Pages 261-266

  Vingert, Benoît ^a,b   Tamagne, Marie ^a,b   Desmarets, Maxime ^a,b   Pakdaman, Sadaf ^a,b   Elayeb, Rahma ^a,b   Habibi, Anoosha ^a   Bernaudin, Françoise ^c   Galacteros, Frédéric ^a,b,d   Bierling, Philippe ^a,b   Noizat Pirenne, France ^a,b,d   Cohen, José ^a,b,d  

^a HENRI MONDOR HOSPITAL   (France)

^b INSERM U955   (France)

^c CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^d UNIVERSITÉ PARIS EST CRÉTEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD39 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HLA DR ANTIGEN;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CELL FUNCTION; CELL POPULATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; MIDDLE AGED; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SICKLE CELL ANEMIA; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

ADULT; ANEMIA, SICKLE CELL; ANTIGENS, CD; BLOOD GROUP ANTIGENS; BLOOD GROUP INCOMPATIBILITY; CTLA-4 ANTIGEN; ERYTHROCYTES; FEMALE; HLA-DR ANTIGENS; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; RECEPTORS, CCR7; T-LYMPHOCYTES, REGULATORY; YOUNG ADULT;

EID: 84896854412     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23903     Document Type: Erratum

References (31)

1. Yazdanbakhsh K, Ware RE, Noizat-Pirenne F. Red blood cell alloimmunization in sickle cell disease: Pathophysiology, risk factors, and transfusion management. Blood 2012;120:528-537.
2. Michel M, Habibi A, Godeau B, et al. Characteristics and outcome of connective tissue diseases in patients with sickle-cell disease: Report of 30 cases. Semin Arthritis Rheum 2008;38:228-240.
3. Toly-Ndour C, Rouquette AM, Obadia S, et al. High titers of autoantibodies in patients with sickle-cell disease. J Rheumatol 2011;38:302-309.
4. Maamar M, Tazi-Mezalek Z, Harmouche H, et al. Systemic lupus erythematosus associated with sickle-cell disease: A case report and literature review. J Med Case Rep 2012;6:366.
5. + regulatory/suppressor T cells in human fetuses. Blood 2005;105:4715-4721.
6. Cohen JL, Trenado A, Vasey D, et al. CD4(+)CD25(+) immunoregulatory T cells: New therapeutics for graft-versus-host disease. J Exp Med 2002;196:401-406.
7. + regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation. Sci Trans Med 2010;2:41ra52.
8. Sagoo P, Ali N, Garg G, et al. Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells. Sci Trans Med 2011;3:83ra42.
9. Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol 2008;8:523-532.
10. Baecher-Allan C, Hafler DA. Human regulatory T cells and their role in autoimmune disease. Immunol Rev 2006;212:203-216.
11. Deaglio S, Dwyer KM, Gao W, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007;204:1257-1265.
12. + Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007;110:1225-1232.
13. Zhang N, Schröppel B, Lal G, et al. Regulatory T cells sequentially migrate from inflamed tissues to draining lymph nodes to suppress the alloimmune response. Immunity 2009;30:458-469.
14. + regulatory T cells. J Exp Med 2007;204:735-745.
15. Baecher-Allan C, Wolf E, Hafler DA. MHC class II expression identifies functionally distinct human regulatory T cells. J Immunol 2006;176:4622-4631.
16. Seddiki N, Santner-Nanan B, Martinson J, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006;203:1693-1700.
17. Liu W, Putnam AL, Xu-Yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006;203:1701-1711.
18. + T cells expressing the FoxP3 transcription factor. Immunity 2009;30:899-911.
19. + regulatory T cell function. Science 2008;322:271-275.
20. Fallarino F, Grohmann U, Hwang KW, et al. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 2003;4:1206-1212.
21. Campbell DJ, Koch MA. Treg cells: Patrolling a dangerous neighborhood. Nat Med 2011;17:929-930.
22. Bao W, Zhong H, Li X, et al. Immune regulation in chronically transfused allo-antibody responder and nonresponder patients with sickle cell disease and β-thalassemia major. Am J Hematol 2011;86:1001-1006.
23. Debes GF, Höpken UE, Hamann A. In vivo differentiated cytokine-producing CD4(+) T cells express functional CCR7. J Immunol 2002;168:5441-5447.
24. Yu J, Heck S, Yazdanbakhsh K. Prevention of red cell alloimmunization by CD25 regulatory T cells in mouse models. Am J Hematol 2007;82:691-696.
25. Bao W, Yu J, Heck S, Yazdanbakhsh K. Regulatory T-cell status in red cell alloimmunized responder and nonresponder mice. Blood 2009;113:5624-5627.
26. + regulatory T cells in the human immune system. Nat Rev Immunol 2010;10:490-500.
27. Hall AO, Beiting DP, Tato C, et al. The cytokines interleukin 27 and interferon-γ promote distinct Treg cell populations required to limit infection-induced pathology. Immunity 2012;37:511-523.
28. Ohkura N, Sakaguchi S. Treg cells acquire new directions, cytokines navigate. Immunity 2012;37:443-444.
29. Belcher JD, Marker PH, Weber JP, et al. Activated monocytes in sickle cell disease: Potential role in the activation of vascular endothelium and vaso-occlusion. Blood 2000;96:2451-2459.
30. Lard LR, Mul FP, de Haas M, Roos D, Duits AJ. Neutrophil activation in sickle cell disease. J Leukoc Biol 1999;66:411-415.
31. Collison LW, Vignali DA. In vitro Treg suppression assays. Meth Mol Biol 2011;707:21-37.